

**BE IT KNOWN** that I, Sunita Kumeri of, 268 Bath Road, Slough, Berkshire United Kingdom a duly authorised Notary Public

## **CERTIFY** that

1. The signature set and subscribed to the certificate at the foot of the first page of the copy document annexed hereto is genuine having been subscribed thereto by Zoe Bruce whose identity I the Notary attest and who is duly authorised by Pfizer Limited ("the Company") to represent them in this matter, and

 Zoe Bruce has thereby certified on behalf of the company that the Certificate of GMP Compliance of a Manufacturer issued to Valdepharm annexed hereto is a true copy of the original document.

SIGNED and sealed at 268 Bath Road, Slough, Berkshire atoresaid on 29th May 2020.

Sunita Kumeri
Notary Public

England and Wales

Protocol No. 2120

	APOSTILLE	ILLE
	(Convention de La Haye du 5 octobre 1961)	du 5 octobre 1961)
ountry:	United Kingdom of Gr	United Kingdom of Great Britain and Northern Ireland
his public document or présent acte public / El pre	'his public document e présent acte public / El presente documento público	úblico
las been signed by 6t6 signé par a sido firmado por	<b>jned by</b>	Sunita Kumeri
Acting in the capaci gissant en qualité de uien actúa en calidad de	Acting in the capacity of gissant en qualité de luien actúa en calidad de	Notary Public
<b>Sears the seal / stamp of the seal / stamp of the sear seal / timbre de setá revestido del sello / timbre de sello / t</b>	Bears the seal / stamp of st revêtu du sceau / timbre de está revestido del sello / timbre de	The Said Notary Public
	Certified Attesté / Certificado	<b>fied</b> ertificado
<b>at</b> á / en	London	<b>6. the</b> 01 June 2020 le / el día
by par / por	Her Majest for Foreig	Her Majesty's Principal Secretary of State for Foreign and Commonwealth Affairs
Number sous no / bajo el numero	I numero	APO-1915003
		### C C

This Apostille is not to be used in the UK and only confirms the authenticity of the signature, seal or stamp on the attached UK public document. Apostilles attached to documents that have been photocopied and certified in the UK confirm the signature of the UK official who conducted the certification only. It does not authenticate either the signature on the original document or the contents of the original document in any way. If this document is to be used in a country not party to the Hague Convention of the 5th of October 1961, it should be presented to the consular section of the mission representing that country

Signature Signature Firma

> TORLICY TORLICY

Seal / stamp Sceau / timbre Sello / timbre To verify this apostille go to www.verifyapostille.service.gov.uk

## French National Agency for Medicines and Health Products Safety

CERTIFICATE NUMBER : 19MPP018HFR01

CERTIFICATE OF GMP COMPLIANCE OF A MANUFACTURER (1), (2)

Part 1

Issued following an inspection in accordance with : Art. 111(5) of Directive 2001/83/EC as amended

The competent authority of France confirms the following:

The manufacturer : VALDEPHARM

Site address PARC INDUSTRIEL D'INCARVILLE, PARC DE LA FRINGALE, CS 10806, VAL DE REUIL (Cedex), 27106, France

Is an active substance manufacturer that has been inspected in accordance with Art. 111(1) of Directive 2001/83/EC.

from the knowledge gained during inspection of this manufacturer, the latest of which was conducted on 2019-01-24, it is considered that it complies

The principles of GMP for active substances (3) referred to in Article 47 of Directive 2001/83/EC

This certificate reflects the status of the manufacturing site at the time of the inspection noted above and should not be relied upon to reflect the compliance status if more than three years have elapsed since the date of that inspection. However, this period of validity may be reduced or extended using regulatory risk management principles by an entry in the Restrictions or Clarifying remarks field. This certificate is valid only when presented with all pages and both Parts 1 and 2.

The authenticity of this certificate may be verified in EudraGMDP. If it does not appear, please contact the issuing authority.

(1) The certificate referred to in paragraph 111(5) of Directive 2001/83/EC and 80(5) of Directive 2001/82/EC, shall also be required for imports coming from third countries into a Member State.
(2) Guidance on the interpretation of this template can be found in the Help menu of EudraGMDP database.
(3) These requirements fulfil the GMP recommendations of WHO.

Manufacture of active substance. Names of substances subject to inspection : [840] BICALUTAMIDE (en) [841] ESTRADIOL BENZOATE (en) [898] ESTRADIOL VALERATE (en) [ 842 ] ESTRAMUSTINE DISODIUM PHOSPHATE MONOHYDRATE ( en [ 338 ] HYDROCORTISONE HYDROGEN SUCCINATE ( en ) [843] IBUPROFEN (en) [1673] NORETHISTERONE (en) [1674] NORETHISTERONE ACETATE (en) [1672] SODIUM ISOSPAGLUMATE (en) [ 200 ] CHLORMADINONE ACETATE (en ) [ 285 ] ESTRADIOL HEMIHYDRATE (en) [ 655 ] MEDROXYPROGESTERONE ACETATE ( en ) [ 421 ] METHYLPREDNISOLONE HYDROGEN SUCCINATE (en ) [ 456 ] NOMEGESTROL ACETATE (en) BENZALKONIUM BROMIDE (en) CLOTIAPINE (en) TRAZODONE HYDROCHLORIDE (en)

## 3. MANUFACTURING OPERATIONS - ACTIVE SUBSTANCES

Active Substance : BICALUTAMIDE

[497] TIXOCORTOL PIVALATE (en)

3.5 General Finishing Steps

3.5.1 Physical processing steps:

3.5.2 Primary Packaging (enclosing / sealing the active substance within a packaging material which is in direct contact with the substance)

3.5.3 Secondary Packaging (placing the sealed primary package within an outer packaging material or container. This also includes any labelling of the material which could be used for identification or traceability (lot numbering) of the active substance)

Active Substance : ESTRADIOL BENZOATE

3.1 Manufacture of Active Substance by Chemical Synthesis

file:///C/Pfizer/GMP%20ML/Valdepharm/searchGMPCompliance.htm[11/22/2019 8:51:02 PM]

100	1.1 Manufacture of active substance intermediates
1	1.2 Manufacture of crude active substance 1.3 Salt formation / Purification steps:
1	1.5 Salt totification / Full induction stope .
1	Seneral Finishing Steps
	the active substance within a nackaging material which is in direct contact with the substance)
	<ul> <li>15.2 Primary Packaging (enclosing) sealing the active substance substance primary package within an outer packaging material or container. This also includes any secondary Packaging (placing the sealed primary package within an outer packaging material or container. This also includes any labelling of the material which could be used for identification or traceability (lot numbering) of the active substance)</li> </ul>
5 0	Quality Control Testing
	3.6.1 Physical / Chemical testing 3.6.2 Microbiological testing excluding sterility testing
ctive	Substance : ESTRADIOL VALERATE
1	Manufacture of Active Substance by Chemical Synthesis
1	3.1.1 Manufacture of active substance intermediates
	3.1.2 Manufacture of crude active substance
	3.1.3 Salt formation / Purification steps:  Recrystallisation
+	Connect Einsching Stans
.5	General Finishing Steps
1	3.5.1 Physical processing steps : Micronisation
	3.5.2 Primary Packaging (enclosing / sealing the active substance within a packaging material which is in direct contact with the substance)
4	3.5.2 Primary Fackaging (enclosing) results of the sealed primary package within an outer packaging material or container. This also includes any labelling of the material which could be used for identification or traceability (lot numbering) of the active substance)
1	
.6	Quality Control Testing
	3.6.1 Physical / Chemical testing
	3.6.2 Microbiological testing excluding sterility testing
	e Substance : ESTRAMUSTINE DISODIUM PHOSPHATE MONOHYDRATE
Т	
3.1	Manufacture of Active Substance by Chemical Synthesis
	3.1.1 Manufacture of active substance intermediates
	3.1.2 Manufacture of crude active substance
	3.1.3 Salt formation / Purification steps :
-	
3.5	General Finishing Steps
	3.5.2 Primary Packaging (enclosing / sealing the active substance within a packaging material which is in direct contact with the substance) 3.5.3 Secondary Packaging (placing the sealed primary package within an outer packaging material or container. This also includes any labelling of the material which could be used for identification or traceability (lot numbering) of the active substance)
3.6	Quality Control Testing
-	
	3.6.1 Physical / Chemical testing 3.6.2 Microbiological testing excluding sterility testing
	U.S. Interesting the second se
Act	ive Substance : HYDROCORTISONE HYDROGEN SUCCINATE
3.1	Manufacture of Active Substance by Chemical Synthesis
3.1	
	3.1.2 Manufacture of crude active substance
	3.1.3 Salt formation / Purification steps : Recrystallisation
2.5	Congral Einjehing Stens
3.5	
	3.5.2 Primary Packaging (enclosing / sealing the active substance within a packaging material which is in direct contact with the substance 3.5.3 Secondary Packaging (placing the sealed primary package within an outer packaging material or container. This also includes any labelling of the material which could be used for identification or traceability (lot numbering) of the active substance)
3.6	
	3.6.1 Physical / Chemical testing 3.6.2 Microbiological testing excluding sterility testing
Ac	ctive Substance : IBUPROFEN
3.	1 Manufacture of Active Substance by Chemical Synthesis
	3.1.3 Salt formation / Purification steps: Recrystallisation
3.	
	3.5.2 Primary Packaging (enclosing / sealing the active substance within a packaging material which is in direct contact with the substance
1	3.3.2 Fillingly Fackaging (encoding) stating and includes any
	3.5.2 Primary Packaging (eliciosing 1 sealing the device between the sealed primary package within an outer packaging material or container. This also includes any labelling of the material which could be used for identification or traceability (lot numbering) of the active substance)
3	3.5.3 Secondary Packaging (placing the sealed primary package within an outer packaging material of container. This area had been sealed primary package within an outer packaging material of container. This area had been sealed primary package within an outer packaging material of container. This area had been sealed primary package within an outer packaging material of container. This area had been sealed primary package within an outer packaging material of container. This area had been sealed primary package within an outer packaging material of container. This area had been sealed primary package within an outer packaging material of container. This area had been sealed primary package within an outer packaging material of container. This area had been sealed primary package within an outer packaging material of container. This area had been sealed primary package within an outer packaging material of container. This area had been sealed primary package within an outer packaging material of container. This area had been sealed primary package within an outer packaging material of container.  3.5.3 Secondary Packaging (placing the sealed primary package within an outer packaging material of container. This area had been sealed primary package within an outer packaging material of container. This area had been sealed primary package within an outer packaging material of container.  3.5.3 Secondary Packaging (placing the sealed primary package within an outer packaging material of container.)
3	labelling of the material which could be used for identification of traceautify (for itemposing) of the material which could be used for identification of traceautify (for itemposing) of the material which could be used for identification of traceautify (for itemposing) of the material which could be used for identification of traceautify (for itemposing) of the material which could be used for identification of traceautify (for itemposing) of the material which could be used for identification of traceautify (for itemposing) of the material which could be used for identification of traceautify (for itemposing) of the material which could be used for identification of traceautify (for itemposing) of the material which could be used for identification of traceautify (for itemposing) of the material which could be used for identification of traceautify (for itemposing) of the material which could be used for identification of traceautification of traceautificatio

3.1	Manufacture of Active Substance by Chemical Synthesis
	3.1.1 Manufacture of active substance intermediates
	3 1.2 Manufacture of crude active substance
	3.1.3 Salt formation / Purification steps : Recrystallisation
3.5	General Finishing Steps
-	3.5.1 Physical processing steps :
	Micronisation
	<ul> <li>3.5.2 Primary Packaging (enclosing / sealing the active substance within a packaging material which is in direct contact with the substance</li> <li>3.5.3 Secondary Packaging (placing the sealed primary package within an outer packaging material or container. This also includes any labelling of the material which could be used for identification or traceability (lot numbering) of the active substance)</li> </ul>
3.6	Quality Control Testing
	3.6.1 Physical / Chemical testing
	3.6.2 Microbiological testing excluding sterility testing
Acti	ve Substance : NORETHISTERONE ACETATE
3.1	Manufacture of Active Substance by Chemical Synthesis
	3.1.1 Manufacture of active substance intermediates
	3.1.2 Manufacture of crude active substance 3.1.3 Salt formation / Purification steps :
	Recrystallisation
3.5	General Finishing Steps
	3.5.1 Physical processing steps : Micronisation
	3.5.2 Primary Packaging (enclosing / sealing the active substance within a packaging material which is in direct contact with the substance
	3.5.3 Secondary Packaging (placing the sealed primary package within an outer packaging material or container. This also includes any labelling of the material which could be used for identification or traceability (lot numbering) of the active substance)
3.6	Quality Control Testing
	3.6.1 Physical / Chemical testing
	3.6.2 Microbiological testing excluding sterility testing
Activ	ve Substance : SODI <mark>UM ISOSPAGLUM</mark> ATE
3.1	Manufacture of Active Substance by Chemical Synthesis
	3.1.1 Manufacture of active substance intermediates
	3.1.2 Manufacture of crude active substance
3.5	General Finishing Steps
	3.5.2 Primary Packaging (enclosing / sealing the active substance within a packaging material which is in direct contact with the substance, 3.5.3 Secondary Packaging (placing the sealed primary package within an outer packaging material or container. This also includes any labelling of the material which could be used for identification or traceability (lot numbering) of the active substance)
3.6	Quality Control Testing
٦	3.6.1 Physical / Chemical testing
	3.6.2 Microbiological testing excluding sterility testing
Activ	re Substance : CHLORMADINONE ACETATE
3.1	Manufacture of Active Substance by Chemical Synthesis
	3.1.1 Manufacture of active substance intermediates
	3.1.2 Manufacture of crude active substance
	3.1.3 Salt formation / Purification steps : Recrystallisation
3,5	General Finishing Steps
	3.5.1 Physical processing steps :
- 1	Micronisation  3.5.2 Primary Packaging (enclosing / sealing the active substance within a packaging material which is in direct contact with the substance
	2.5.0 Community of the state of
	3.5.3 Secondary Packaging (placing the sealed primary package within an outer packaging material or container. This also includes any
	racealing of the material which could be used for identification of traceability (lot numbering) of the active substance)
3.6	Quality Control Testing
3.6	racealing of the material which could be used for identification of traceability (lot numbering) of the active substance)
	Quality Control Testing  3.6.1 Physical / Chemical testing
Activ	Quality Control Testing  3.6.1 Physical / Chemical testing 3.6.2 Microbiological testing excluding sterility testing
Activ	Quality Control Testing  3.6.1 Physical / Chemical testing 3.6.2 Microbiological testing excluding sterility testing  e Substance : ESTRADIOL HEMIHYDRATE
3.6 Activ	Quality Control Testing  3.6.1 Physical / Chemical testing 3.6.2 Microbiological testing excluding sterility testing  e Substance : ESTRADIOL HEMIHYDRATE  Manufacture of Active Substance by Chemical Synthesis  3.1.1 Manufacture of active substance intermediates 3.1.2 Manufacture of crude active substance
Activ	Quality Control Testing  3.6.1 Physical / Chemical testing 3.6.2 Microbiological testing excluding sterility testing  e Substance : ESTRADIOL HEMIHYDRATE  Manufacture of Active Substance by Chemical Synthesis  3.1.1 Manufacture of active substance intermediates

	3.5.1 Physical processing steps: Micronisation
	<ul> <li>3.5.2 Primary Packaging (enclosing / sealing the active substance within a packaging material which is in dred consider the substance)</li> <li>3.5.3 Secondary Packaging (placing the sealed primary package within an outer packaging material or consider This also includes any</li> </ul>
	3.5.3 Secondary Packaging (placing the sealed printary package within an other package within an other packaging (placing the sealed printary package within an other package) of the sealed printary package within an other package within a package within an other package within a package within an other package within an other package within an other package within an other package within
.6	Quality Control Testing
+	
	3.6.1 Physical / Chemical testing 3.6.2 Microbiological testing excluding sterility testing
ctive	e Substance : MEDROXYPROGESTERONE ACETATE
.1	Manufacture of Active Substance by Chemical Synthesis
7	3.1.1 Manufacture of active substance intermediates
1	3.1.2 Manufacture of crude active substance
	3.1.3 Salt formation / Purification steps : Recrystallisation
.5	General Finishing Steps
7	3.5.1 Physical processing steps :
	Micronisation 3.5.2 Primary Packaging (enclosing / sealing the active substance within a packaging material which is in direct contact with the substance)
	3.5.2 Filling y Fackaging (nacionally is sealing the content of the secondary Packaging (nacional the sealed primary package within an outer packaging material or container. This also includes any labelling of the material which could be used for identification or traceability (lot numbering) of the active substance)
3.6	Quality Control Testing
	3,6,1 Physical / Chemical testing
	3.6.2 Microbiological testing excluding sterility testing
Activ	ve Substance : METHYLPREDNISOLONE HYDROGEN SUCCINATE
3.1	Manufacture of Active Substance by Chemical Synthesis
	3.1.1 Manufacture of active substance intermediates
	3.1.2 Manufacture of crude active substance
	3.1.3 Salt formation / Purification steps:
3.5	General Finishing Steps
	3.5.2 Primary Packaging (enclosing / sealing the active substance within a packaging material which is in direct contact with the substance
	3.5.3 Secondary Packaging (placing the sealed primary package within an outer packaging material or container. This also includes any labelling of the material which could be used for identification or traceability (lot numbering) of the active substance)
3.6	Quality Control Testing
	3.6.1 Physical / Chemical testing
	3.6.2 Microbiological testing excluding sterility testing
Act	ive Substance : NOMEGESTROL ACETATE
3.5	General Finishing Steps
	3.5.1 Physical processing steps :
	Micronisation
	3.5.2 Primary Packaging (enclosing / sealing the active substance within a packaging material which is in direct contact with the substance 3.5.3 Secondary Packaging (placing the sealed primary package within an outer packaging material or container. This also includes any labelling of the material which could be used for identification or traceability (lot numbering) of the active substance)
Act	tive Substance : BENZALKONIUM BROMIDE
3.1	
	3.1.2 Manufacture of crude active substance
2.5	
3.5	this analogical which is in direct contact with the substance
3.6	Quality Control Testing
	3.6.1 Physical / Chemical testing
Ad	tive Substance : CLOTIAPINE
3.	1 Manufacture of Active Substance by Chemical Synthesis
	3.1.2 Manufacture of crude active substance
	3.1.3 Salt formation / Purification steps :
	Recrystallisation
	5 General Finishing Steps
3.	
3.	3.5.2 Primary Packaging (enclosing / sealing the active substance within a packaging material which is in direct contact with the substance 3.5.3 Secondary Packaging (placing the sealed primary package within an outer packaging material or container. This also includes any labelling of the material which could be used for identification or traceability (lot numbering) of the active substance)
3.:	labelling of the material which could be used for identification or traceability (for numbering) of the active substance)

3.6.1 Physical / Chemical testing

	ve Substance : TRAZODONE HYDROCHLORIDE
3.1	Manufacture of Active Substance by Chemical Synthesis
3.1	manufacture of Active Substance by Chemical Synthesis
	3.1.1 Manufacture of active substance intermediates
	3.1.2 Manufacture of crude active substance
	3.1.3 Salt formation / Purification steps:
3.5	General Finishing Steps
	3.5.2 Primary Packaging (enclosing / sealing the active substance within a packaging material which is in direct contact with the substance
	3.5.3 Secondary Packaging (placing the sealed primary package within an outer packaging material or container. This also includes any
	labelling of the material which could be used for identification or traceability (lot numbering) of the active substance)
3.6	Quality Control Testing
*	
	3.6.1 Physical / Chemical testing
Acti	3.6.1 Physical / Chemical testing  ve Substance : TIXOCORTOL PIVALATE
Acti	
-	ve Substance : TIXOCORTOL PIVALATE
-	ve Substance : TIXOCORTOL PIVALATE  Manufacture of Active Substance by Chemical Synthesis
-	ve Substance : TIXOCORTOL PIVALATE  Manufacture of Active Substance by Chemical Synthesis  3.1.1 Manufacture of active substance intermediates
-	ve Substance : TIXOCORTOL PIVALATE  Manufacture of Active Substance by Chemical Synthesis  3.1.1 Manufacture of active substance intermediates  3.1.2 Manufacture of crude active substance
3.1	we Substance : TIXOCORTOL PIVALATE  Manufacture of Active Substance by Chemical Synthesis  3.1.1 Manufacture of active substance intermediates 3.1.2 Manufacture of crude active substance 3.1.3 Salt formation / Purification steps :  General Finishing Steps
3.1	we Substance : TIXOCORTOL PIVALATE  Manufacture of Active Substance by Chemical Synthesis  3.1.1 Manufacture of active substance intermediates 3.1.2 Manufacture of crude active substance 3.1.3 Salt formation / Purification steps :  General Finishing Steps
3.1	we Substance: TIXOCORTOL PIVALATE  Manufacture of Active Substance by Chemical Synthesis  3.1.1 Manufacture of active substance intermediates 3.1.2 Manufacture of crude active substance 3.1.3 Salt formation / Purification steps:  General Finishing Steps  3.5.2 Primary Packaging (enclosing / sealing the active substance within a packaging material which is in direct contact with the substance; 3.5.3 Secondary Packaging (placing the sealed primary package within an outer packaging material or container. This also includes any

Clarifying remarks (for public users):

Estradiol hemihydrate is synthetised from estrone / Sodium Isopaglumate is also known as naaga salt / Ethinylestradiol is micronised by a contract manufacturer / Signatory: Mrs Linda Gallais, head of starting materials inspection department — The ANSM does not issue hard copies of good practices certificates

2019-05-15

Name and signature of the authorised person of the Competent Authority of France

Confidential

French National Agency for Medicines and Health Products Safety

Tel: Confidential

The EudraGMDP database is maintained and operated by the EMA. Access to the general public is granted in order to enhance availability of information related to the EMA mandate. The content of the database is provided by the National Competent Authorities (NCA) of the EEA For this reason, the EMA accepts no responsibility or liability whatsoever (including but not limited to any direct or consequential loss or damage it might occur to you and/or any other third party) arising out of or in connection with the information on this database. Any questions about the content should be addressed to the relevant NCA. Please click here to get list of NCA's.

[EMA © 2014 EudraGMDP 6.4.4.0 build 2019/09/23 08:29]